APO Research
Talk to an analyst

APO RESEARCH · REPORT

T Cell Surface Glycoprotein CD3 Epsilon

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global T Cell Surface Glycoprotein CD3 Epsilon Market Outlook and Growth Opportunities 2026

19 December 2025199 pages

Choose your research edition.

Industry ResearchT Cell Surface Glycoprotein CD3 Epsilon Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal T Cell Surface Glycoprotein CD3 Epsilon Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal T Cell Surface Glycoprotein CD3 Epsilon Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal T Cell Surface Glycoprotein CD3 Epsilon Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal T Cell Surface Glycoprotein CD3 Epsilon Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global T Cell Surface Glycoprotein CD3 Epsilon market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for T Cell Surface Glycoprotein CD3 Epsilon is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for T Cell Surface Glycoprotein CD3 Epsilon is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for T Cell Surface Glycoprotein CD3 Epsilon is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the T Cell Surface Glycoprotein CD3 Epsilon market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the T Cell Surface Glycoprotein CD3 Epsilon market include GlaxoSmithKline Plc, Amgen Inc, Tiziana Life Sciences Plc, SYNIMMUNE GmbH, Numab Innovation AG, Meridigen Biotech Co Ltd, MacroGenics Inc, F. Hoffmann-La Roche Ltd and Celgene Corp, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global T Cell Surface Glycoprotein CD3 Epsilon market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of T Cell Surface Glycoprotein CD3 Epsilon and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents T Cell Surface Glycoprotein CD3 Epsilon revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global T Cell Surface Glycoprotein CD3 Epsilon market.

T Cell Surface Glycoprotein CD3 Epsilon Segment by Company

GlaxoSmithKline Plc

Amgen Inc

Tiziana Life Sciences Plc

SYNIMMUNE GmbH

Numab Innovation AG

Meridigen Biotech Co Ltd

MacroGenics Inc

F. Hoffmann-La Roche Ltd

Celgene Corp

T Cell Surface Glycoprotein CD3 Epsilon Segment by Type

ND-007

Foralumab

Coltelizumab

AVA-002

Others

T Cell Surface Glycoprotein CD3 Epsilon Segment by Application

Autoimmune Disorders

Hepatitis B

Prostate Cancer

Multiple Sclerosis

Others

T Cell Surface Glycoprotein CD3 Epsilon Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global T Cell Surface Glycoprotein CD3 Epsilon status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the T Cell Surface Glycoprotein CD3 Epsilon key companies, revenue, market share, and recent developments.

3. To split the T Cell Surface Glycoprotein CD3 Epsilon breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions T Cell Surface Glycoprotein CD3 Epsilon market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify T Cell Surface Glycoprotein CD3 Epsilon significant trends, drivers, influence factors in global and regions.

6. To analyze T Cell Surface Glycoprotein CD3 Epsilon competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global T Cell Surface Glycoprotein CD3 Epsilon market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of T Cell Surface Glycoprotein CD3 Epsilon and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of T Cell Surface Glycoprotein CD3 Epsilon.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global T Cell Surface Glycoprotein CD3 Epsilon industry.

Chapter 3: Detailed analysis of T Cell Surface Glycoprotein CD3 Epsilon company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of T Cell Surface Glycoprotein CD3 Epsilon in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of T Cell Surface Glycoprotein CD3 Epsilon in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. T Cell Surface Glycoprotein CD3 Epsilon Industry Trends Table 2. T Cell Surface Glycoprotein CD3 Epsilon Industry Drivers Table 3. T Cell Surface Glycoprotein CD3 Epsilon Industry Opportunities and Challenges Table 4. T Cell Surface Glycoprotein CD3 Epsilon Industry Restraints Table 5. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Company (US$ Million) & (2021-2026) Table 6. Global T Cell Surface Glycoprotein CD3 Epsilon Revenue Share by Company (2021-2026) Table 7. Global T Cell Surface Glycoprotein CD3 Epsilon Company Ranking, (2024-2026) & (US$ Million) Table 8. Global T Cell Surface Glycoprotein CD3 Epsilon Key Company Manufacturing Base & Headquarters Table 9. Global T Cell Surface Glycoprotein CD3 Epsilon Company, Product Type & Application Table 10. Global T Cell Surface Glycoprotein CD3 Epsilon Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global T Cell Surface Glycoprotein CD3 Epsilon by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of ND-007 Table 15. Significant Companies of Foralumab Table 16. Significant Companies of Coltelizumab Table 17. Significant Companies of AVA-002 Table 18. Significant Companies of Others Table 19. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type (2021-2026) Table 23. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Autoimmune Disorders Table 25. Significant Companies of Hepatitis B Table 26. Significant Companies of Prostate Cancer Table 27. Significant Companies of Multiple Sclerosis Table 28. Significant Companies of Others Table 29. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Application (2021-2026) & (US$ Million) Table 31. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Application (2027-2032) & (US$ Million) Table 32. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application (2021-2026) Table 33. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application (2027-2032) Table 34. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Region (2021-2026) & (US$ Million) Table 36. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Region (2021-2026) Table 37. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Region (2027-2032) & (US$ Million) Table 38. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Region (2027-2032) Table 39. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Country (2021-2026) & (US$ Million) Table 41. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Market Share by Country (2021-2026) Table 42. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Country (2027-2032) & (US$ Million) Table 43. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Market Share by Country (2027-2032) Table 44. GlaxoSmithKline Plc Company Information Table 45. GlaxoSmithKline Plc Business Overview Table 46. GlaxoSmithKline Plc T Cell Surface Glycoprotein CD3 Epsilon Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. GlaxoSmithKline Plc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 48. GlaxoSmithKline Plc Recent Development Table 49. Amgen Inc Company Information Table 50. Amgen Inc Business Overview Table 51. Amgen Inc T Cell Surface Glycoprotein CD3 Epsilon Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Amgen Inc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 53. Amgen Inc Recent Development Table 54. Tiziana Life Sciences Plc Company Information Table 55. Tiziana Life Sciences Plc Business Overview Table 56. Tiziana Life Sciences Plc T Cell Surface Glycoprotein CD3 Epsilon Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Tiziana Life Sciences Plc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 58. Tiziana Life Sciences Plc Recent Development Table 59. SYNIMMUNE GmbH Company Information Table 60. SYNIMMUNE GmbH Business Overview Table 61. SYNIMMUNE GmbH T Cell Surface Glycoprotein CD3 Epsilon Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. SYNIMMUNE GmbH T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 63. SYNIMMUNE GmbH Recent Development Table 64. Numab Innovation AG Company Information Table 65. Numab Innovation AG Business Overview Table 66. Numab Innovation AG T Cell Surface Glycoprotein CD3 Epsilon Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Numab Innovation AG T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 68. Numab Innovation AG Recent Development Table 69. Meridigen Biotech Co Ltd Company Information Table 70. Meridigen Biotech Co Ltd Business Overview Table 71. Meridigen Biotech Co Ltd T Cell Surface Glycoprotein CD3 Epsilon Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Meridigen Biotech Co Ltd T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 73. Meridigen Biotech Co Ltd Recent Development Table 74. MacroGenics Inc Company Information Table 75. MacroGenics Inc Business Overview Table 76. MacroGenics Inc T Cell Surface Glycoprotein CD3 Epsilon Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. MacroGenics Inc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 78. MacroGenics Inc Recent Development Table 79. F. Hoffmann-La Roche Ltd Company Information Table 80. F. Hoffmann-La Roche Ltd Business Overview Table 81. F. Hoffmann-La Roche Ltd T Cell Surface Glycoprotein CD3 Epsilon Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. F. Hoffmann-La Roche Ltd T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 83. F. Hoffmann-La Roche Ltd Recent Development Table 84. Celgene Corp Company Information Table 85. Celgene Corp Business Overview Table 86. Celgene Corp T Cell Surface Glycoprotein CD3 Epsilon Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Celgene Corp T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio Table 88. Celgene Corp Recent Development Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. T Cell Surface Glycoprotein CD3 Epsilon Product Image Figure 2. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global T Cell Surface Glycoprotein CD3 Epsilon Market Size (2021-2032) & (US$ Million) Figure 4. Global T Cell Surface Glycoprotein CD3 Epsilon Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. ND-007 Image Figure 8. Foralumab Image Figure 9. Coltelizumab Image Figure 10. AVA-002 Image Figure 11. Others Image Figure 12. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type (2021-2032) Figure 15. Autoimmune Disorders Image Figure 16. Hepatitis B Image Figure 17. Prostate Cancer Image Figure 18. Multiple Sclerosis Image Figure 19. Others Image Figure 20. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application (2021-2032) Figure 23. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 24. Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 25. North America T Cell Surface Glycoprotein CD3 Epsilon Sales Value (2021-2032) & (US$ Million) Figure 26. North America T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Europe T Cell Surface Glycoprotein CD3 Epsilon Sales Value (2021-2032) & (US$ Million) Figure 28. Europe T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Asia-Pacific T Cell Surface Glycoprotein CD3 Epsilon Sales Value (2021-2032) & (US$ Million) Figure 30. Asia-Pacific T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Country (%), 2025 VS 2032 Figure 31. South America T Cell Surface Glycoprotein CD3 Epsilon Sales Value (2021-2032) & (US$ Million) Figure 32. South America T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Middle East & Africa T Cell Surface Glycoprotein CD3 Epsilon Sales Value (2021-2032) & (US$ Million) Figure 34. Middle East & Africa T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Country (%), 2025 VS 2032 Figure 35. USA T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. USA T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. USA T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Canada T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Canada T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Canada T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Mexico T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Mexico T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Mexico T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Germany T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Germany T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Germany T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. France T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. France T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. France T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. U.K. T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. U.K. T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. U.K. T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Italy T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Italy T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Italy T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Spain T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Spain T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Spain T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Russia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Russia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Russia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Netherlands T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Netherlands T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Netherlands T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Nordic Countries T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Nordic Countries T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Nordic Countries T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. China T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. China T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. China T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Japan T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Japan T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Japan T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. South Korea T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. South Korea T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. South Korea T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. India T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. India T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. India T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Australia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Australia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Australia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Southeast Asia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Southeast Asia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Southeast Asia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Brazil T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Brazil T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Brazil T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Argentina T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Argentina T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Argentina T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Chile T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Chile T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Chile T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Colombia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Colombia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Colombia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Peru T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Peru T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Peru T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Saudi Arabia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Saudi Arabia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Saudi Arabia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Israel T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Israel T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Israel T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. UAE T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. UAE T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. UAE T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Turkey T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Turkey T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Turkey T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Iran T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Iran T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Iran T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Egypt T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Egypt T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Egypt T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Years Considered Figure 120. Research Process Figure 121. Key Executives Interviewed

Scope & coverage.

Types
  • ND-007
  • Foralumab
  • Coltelizumab
  • AVA-002
  • Others
Applications
  • Autoimmune Disorders
  • Hepatitis B
  • Prostate Cancer
  • Multiple Sclerosis
  • Others
Companies covered
  • GlaxoSmithKline Plc
  • Amgen Inc
  • Tiziana Life Sciences Plc
  • SYNIMMUNE GmbH
  • Numab Innovation AG
  • Meridigen Biotech Co Ltd
  • MacroGenics Inc
  • F. Hoffmann-La Roche Ltd
  • Celgene Corp

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global T Cell Surface Glycoprotein CD3 Epsilon Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global T Cell Surface Glycoprotein CD3 Epsilon Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 T Cell Surface Glycoprotein CD3 Epsilon Market Dynamics
  1. 2.1 T Cell Surface Glycoprotein CD3 Epsilon Industry Trends
  2. 2.2 T Cell Surface Glycoprotein CD3 Epsilon Industry Drivers
  3. 2.3 T Cell Surface Glycoprotein CD3 Epsilon Industry Opportunities and Challenges
  4. 2.4 T Cell Surface Glycoprotein CD3 Epsilon Industry Restraints
3 T Cell Surface Glycoprotein CD3 Epsilon Market by Company
  1. 3.1 Global T Cell Surface Glycoprotein CD3 Epsilon Company Revenue Ranking in 2025
  2. 3.2 Global T Cell Surface Glycoprotein CD3 Epsilon Revenue by Company (2021-2026)
  3. 3.3 Global T Cell Surface Glycoprotein CD3 Epsilon Company Ranking (2024-2026)
  4. 3.4 Global T Cell Surface Glycoprotein CD3 Epsilon Company Manufacturing Base and Headquarters
  5. 3.5 Global T Cell Surface Glycoprotein CD3 Epsilon Company Product Type and Application
  6. 3.6 Global T Cell Surface Glycoprotein CD3 Epsilon Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global T Cell Surface Glycoprotein CD3 Epsilon Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 T Cell Surface Glycoprotein CD3 Epsilon Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 T Cell Surface Glycoprotein CD3 Epsilon Market by Type
  1. 4.1 T Cell Surface Glycoprotein CD3 Epsilon Type Introduction
  2. 4.1.1 ND-007
  3. 4.1.2 Foralumab
  4. 4.1.3 Coltelizumab
  5. 4.1.4 AVA-002
  6. 4.1.5 Others
  7. 4.2 Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Type
  8. 4.2.1 Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Type (2021-2032)
  10. 4.2.3 Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type (2021-2032)
5 T Cell Surface Glycoprotein CD3 Epsilon Market by Application
  1. 5.1 T Cell Surface Glycoprotein CD3 Epsilon Application Introduction
  2. 5.1.1 Autoimmune Disorders
  3. 5.1.2 Hepatitis B
  4. 5.1.3 Prostate Cancer
  5. 5.1.4 Multiple Sclerosis
  6. 5.1.5 Others
  7. 5.2 Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Application
  8. 5.2.1 Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Application (2021-2032)
  10. 5.2.3 Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application (2021-2032)
6 T Cell Surface Glycoprotein CD3 Epsilon Regional Value Analysis
  1. 6.1 Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Region (2021-2032)
  3. 6.2.1 Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Region: 2021-2026
  4. 6.2.2 Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America T Cell Surface Glycoprotein CD3 Epsilon Sales Value (2021-2032)
  7. 6.3.2 North America T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe T Cell Surface Glycoprotein CD3 Epsilon Sales Value (2021-2032)
  10. 6.4.2 Europe T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific T Cell Surface Glycoprotein CD3 Epsilon Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America T Cell Surface Glycoprotein CD3 Epsilon Sales Value (2021-2032)
  16. 6.6.2 South America T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa T Cell Surface Glycoprotein CD3 Epsilon Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Country, 2025 VS 2032
7 T Cell Surface Glycoprotein CD3 Epsilon Country-level Value Analysis
  1. 7.1 Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Country (2021-2032)
  3. 7.2.1 Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Country (2021-2026)
  4. 7.2.2 Global T Cell Surface Glycoprotein CD3 Epsilon Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt T Cell Surface Glycoprotein CD3 Epsilon Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt T Cell Surface Glycoprotein CD3 Epsilon Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GlaxoSmithKline Plc
  2. 8.1.1 GlaxoSmithKline Plc Company Information
  3. 8.1.2 GlaxoSmithKline Plc Business Overview
  4. 8.1.3 GlaxoSmithKline Plc T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GlaxoSmithKline Plc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  6. 8.1.5 GlaxoSmithKline Plc Recent Developments
  7. 8.2 Amgen Inc
  8. 8.2.1 Amgen Inc Company Information
  9. 8.2.2 Amgen Inc Business Overview
  10. 8.2.3 Amgen Inc T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Amgen Inc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  12. 8.2.5 Amgen Inc Recent Developments
  13. 8.3 Tiziana Life Sciences Plc
  14. 8.3.1 Tiziana Life Sciences Plc Company Information
  15. 8.3.2 Tiziana Life Sciences Plc Business Overview
  16. 8.3.3 Tiziana Life Sciences Plc T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Tiziana Life Sciences Plc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  18. 8.3.5 Tiziana Life Sciences Plc Recent Developments
  19. 8.4 SYNIMMUNE GmbH
  20. 8.4.1 SYNIMMUNE GmbH Company Information
  21. 8.4.2 SYNIMMUNE GmbH Business Overview
  22. 8.4.3 SYNIMMUNE GmbH T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  23. 8.4.4 SYNIMMUNE GmbH T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  24. 8.4.5 SYNIMMUNE GmbH Recent Developments
  25. 8.5 Numab Innovation AG
  26. 8.5.1 Numab Innovation AG Company Information
  27. 8.5.2 Numab Innovation AG Business Overview
  28. 8.5.3 Numab Innovation AG T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Numab Innovation AG T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  30. 8.5.5 Numab Innovation AG Recent Developments
  31. 8.6 Meridigen Biotech Co Ltd
  32. 8.6.1 Meridigen Biotech Co Ltd Company Information
  33. 8.6.2 Meridigen Biotech Co Ltd Business Overview
  34. 8.6.3 Meridigen Biotech Co Ltd T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Meridigen Biotech Co Ltd T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  36. 8.6.5 Meridigen Biotech Co Ltd Recent Developments
  37. 8.7 MacroGenics Inc
  38. 8.7.1 MacroGenics Inc Company Information
  39. 8.7.2 MacroGenics Inc Business Overview
  40. 8.7.3 MacroGenics Inc T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  41. 8.7.4 MacroGenics Inc T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  42. 8.7.5 MacroGenics Inc Recent Developments
  43. 8.8 F. Hoffmann-La Roche Ltd
  44. 8.8.1 F. Hoffmann-La Roche Ltd Company Information
  45. 8.8.2 F. Hoffmann-La Roche Ltd Business Overview
  46. 8.8.3 F. Hoffmann-La Roche Ltd T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  47. 8.8.4 F. Hoffmann-La Roche Ltd T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  48. 8.8.5 F. Hoffmann-La Roche Ltd Recent Developments
  49. 8.9 Celgene Corp
  50. 8.9.1 Celgene Corp Company Information
  51. 8.9.2 Celgene Corp Business Overview
  52. 8.9.3 Celgene Corp T Cell Surface Glycoprotein CD3 Epsilon Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Celgene Corp T Cell Surface Glycoprotein CD3 Epsilon Product Portfolio
  54. 8.9.5 Celgene Corp Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst